| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 21 | 2025 | 2471 | 1.860 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 465 | 1.720 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 327 | 1.720 |
Why?
|
| High-Throughput Nucleotide Sequencing | 11 | 2025 | 261 | 1.690 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2021 | 62 | 1.300 |
Why?
|
| DNA Mutational Analysis | 11 | 2025 | 196 | 0.850 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 24 | 0.810 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2016 | 155 | 0.780 |
Why?
|
| Immunohistochemistry | 17 | 2023 | 854 | 0.750 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 299 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2025 | 239 | 0.710 |
Why?
|
| Urothelium | 2 | 2020 | 22 | 0.700 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2021 | 24 | 0.700 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 53 | 0.680 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2025 | 170 | 0.650 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 327 | 0.640 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 8 | 0.630 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 30 | 0.620 |
Why?
|
| Thymosin | 4 | 2007 | 8 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 99 | 0.610 |
Why?
|
| Hemangiosarcoma | 2 | 2015 | 24 | 0.600 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 127 | 0.590 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2025 | 74 | 0.570 |
Why?
|
| Middle Aged | 33 | 2025 | 16535 | 0.560 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 44 | 0.560 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 68 | 0.540 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 10 | 0.540 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 15 | 0.530 |
Why?
|
| Aged | 29 | 2025 | 13581 | 0.520 |
Why?
|
| Humans | 67 | 2025 | 60132 | 0.490 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.490 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 201 | 0.470 |
Why?
|
| Lung Diseases | 1 | 2016 | 166 | 0.460 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 330 | 0.460 |
Why?
|
| Simplexvirus | 5 | 1995 | 25 | 0.460 |
Why?
|
| Adult | 22 | 2025 | 15985 | 0.450 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 5197 | 0.450 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 33 | 0.450 |
Why?
|
| Human papillomavirus 16 | 2 | 2021 | 17 | 0.430 |
Why?
|
| Female | 35 | 2025 | 31250 | 0.430 |
Why?
|
| Anus Neoplasms | 2 | 2025 | 23 | 0.420 |
Why?
|
| Male | 37 | 2025 | 27971 | 0.420 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 56 | 0.410 |
Why?
|
| Viral Proteins | 4 | 1995 | 261 | 0.400 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.390 |
Why?
|
| Endothelial Cells | 3 | 2022 | 177 | 0.390 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2021 | 7 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 419 | 0.380 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 29 | 0.380 |
Why?
|
| Stem Cell Transplantation | 2 | 2011 | 75 | 0.370 |
Why?
|
| Myofibroblasts | 1 | 2010 | 12 | 0.360 |
Why?
|
| Endothelium | 1 | 2010 | 18 | 0.360 |
Why?
|
| Urine | 2 | 2021 | 36 | 0.360 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2024 | 20 | 0.350 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 460 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 203 | 0.350 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 232 | 0.330 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 6 | 0.320 |
Why?
|
| Receptor, ErbB-4 | 2 | 2019 | 8 | 0.320 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2019 | 10 | 0.320 |
Why?
|
| Cyst Fluid | 2 | 2019 | 5 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 118 | 0.310 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 75 | 0.300 |
Why?
|
| Carcinoma | 2 | 2020 | 117 | 0.290 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 1132 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 316 | 0.290 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 114 | 0.290 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 1100 | 0.280 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 910 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 207 | 0.280 |
Why?
|
| Prognosis | 5 | 2025 | 1591 | 0.270 |
Why?
|
| Cell Fusion | 4 | 1995 | 45 | 0.270 |
Why?
|
| ras Proteins | 3 | 2016 | 78 | 0.270 |
Why?
|
| CD56 Antigen | 2 | 2021 | 15 | 0.260 |
Why?
|
| Repressor Proteins | 3 | 2024 | 336 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 184 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 405 | 0.250 |
Why?
|
| MafG Transcription Factor | 2 | 2016 | 5 | 0.250 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2025 | 4 | 0.250 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 8 | 0.250 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 196 | 0.240 |
Why?
|
| Histiocytic Sarcoma | 2 | 2016 | 4 | 0.230 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 75 | 0.230 |
Why?
|
| Proctitis | 1 | 2023 | 6 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 449 | 0.220 |
Why?
|
| Nevus | 1 | 2024 | 18 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 171 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2014 | 51 | 0.220 |
Why?
|
| Viral Envelope Proteins | 3 | 1993 | 111 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 77 | 0.210 |
Why?
|
| CpG Islands | 2 | 2014 | 212 | 0.210 |
Why?
|
| Survival Rate | 4 | 2020 | 793 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 387 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2016 | 379 | 0.200 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 24 | 0.200 |
Why?
|
| beta Catenin | 2 | 2021 | 85 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 262 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 31 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 498 | 0.190 |
Why?
|
| Uterine Neoplasms | 2 | 2020 | 31 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1035 | 0.190 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 15 | 0.190 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 12 | 0.190 |
Why?
|
| Melanoma | 2 | 2016 | 335 | 0.180 |
Why?
|
| Anal Canal | 1 | 2021 | 34 | 0.180 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 55 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 29 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2021 | 36 | 0.180 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 12 | 0.180 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 56 | 0.180 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.180 |
Why?
|
| Leukocytosis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Adenosarcoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 59 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.170 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 13 | 0.170 |
Why?
|
| DNA-Binding Proteins | 3 | 2024 | 1136 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2020 | 17 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 29 | 0.170 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 13 | 0.170 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 18 | 0.170 |
Why?
|
| Oncogenes | 2 | 2018 | 69 | 0.160 |
Why?
|
| Thiazolidines | 1 | 2019 | 15 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 760 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 29 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2020 | 201 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 2362 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2022 | 124 | 0.160 |
Why?
|
| Animals | 18 | 2022 | 19768 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 11 | 0.160 |
Why?
|
| Pancreas | 1 | 2019 | 146 | 0.160 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2019 | 32 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 65 | 0.160 |
Why?
|
| Young Adult | 5 | 2025 | 4396 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 142 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 193 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 10 | 0.150 |
Why?
|
| DNA Methylation | 3 | 2016 | 273 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 39 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 398 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 24 | 0.150 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 58 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 272 | 0.140 |
Why?
|
| Lymph Nodes | 3 | 2018 | 215 | 0.140 |
Why?
|
| Immunophenotyping | 5 | 2021 | 185 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 577 | 0.140 |
Why?
|
| Disease Progression | 5 | 2024 | 1054 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 153 | 0.140 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 8 | 0.140 |
Why?
|
| 5-Methylcytosine | 1 | 2016 | 20 | 0.140 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1983 | 0.130 |
Why?
|
| Lipase | 1 | 2017 | 49 | 0.130 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 298 | 0.130 |
Why?
|
| Laboratories | 1 | 2016 | 26 | 0.130 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 15 | 0.130 |
Why?
|
| Sarcoma | 1 | 2016 | 36 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 351 | 0.130 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 196 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6139 | 0.130 |
Why?
|
| Liver | 1 | 2020 | 789 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 45 | 0.120 |
Why?
|
| PAX5 Transcription Factor | 2 | 2012 | 12 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 697 | 0.120 |
Why?
|
| Biopsy | 1 | 2016 | 376 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 26 | 0.120 |
Why?
|
| Vero Cells | 5 | 1995 | 76 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 793 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2016 | 365 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 75 | 0.120 |
Why?
|
| Fixatives | 1 | 2014 | 17 | 0.120 |
Why?
|
| Fatal Outcome | 4 | 2020 | 114 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 405 | 0.120 |
Why?
|
| Benzamides | 1 | 2014 | 51 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 302 | 0.110 |
Why?
|
| Glycoproteins | 2 | 1993 | 194 | 0.110 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 72 | 0.110 |
Why?
|
| Mice | 7 | 2022 | 10343 | 0.110 |
Why?
|
| Genes, ras | 1 | 2014 | 28 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 3131 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 81 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1589 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 31 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 236 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 38 | 0.110 |
Why?
|
| Breast | 1 | 2015 | 173 | 0.110 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2013 | 7 | 0.110 |
Why?
|
| Mastocytosis, Systemic | 1 | 2013 | 6 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2013 | 3 | 0.110 |
Why?
|
| Mast Cells | 1 | 2013 | 41 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 15 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 26 | 0.100 |
Why?
|
| Melanocytes | 1 | 2013 | 78 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 46 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 136 | 0.100 |
Why?
|
| Adolescent | 3 | 2023 | 5958 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 45 | 0.100 |
Why?
|
| Carboplatin | 1 | 2012 | 40 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 27 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2012 | 60 | 0.100 |
Why?
|
| Pyrazines | 1 | 2012 | 32 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2011 | 21 | 0.100 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 12 | 0.100 |
Why?
|
| Viral Fusion Proteins | 1 | 1992 | 74 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 19 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 103 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 483 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2011 | 57 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 183 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 835 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.090 |
Why?
|
| Metaplasia | 1 | 2010 | 18 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 277 | 0.090 |
Why?
|
| Phenotype | 3 | 2025 | 1158 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 147 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 80 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2010 | 65 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2024 | 28 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 225 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 848 | 0.080 |
Why?
|
| Genes, Viral | 3 | 1995 | 56 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 1384 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Trisomy | 1 | 2008 | 19 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 376 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2087 | 0.070 |
Why?
|
| Recurrence | 2 | 2008 | 600 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 33 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 64 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 113 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 119 | 0.070 |
Why?
|
| Transcription Factors | 4 | 2021 | 1459 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2006 | 9 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2001 | 492 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 665 | 0.060 |
Why?
|
| United States | 2 | 2016 | 7622 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2005 | 28 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 138 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 30 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2005 | 51 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 67 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 172 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 860 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2014 | 24 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 254 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2023 | 4 | 0.060 |
Why?
|
| Ulcer | 1 | 2023 | 15 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1565 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 324 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2014 | 38 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2022 | 25 | 0.050 |
Why?
|
| Adenoviridae | 2 | 1993 | 120 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 18 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 35 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2013 | 189 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2021 | 2891 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1066 | 0.050 |
Why?
|
| Glycosylation | 2 | 1992 | 135 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 53 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 34 | 0.050 |
Why?
|
| Chromogranins | 1 | 2021 | 12 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2001 | 48 | 0.050 |
Why?
|
| Cadherins | 1 | 2021 | 69 | 0.050 |
Why?
|
| Urinalysis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Embryo Loss | 1 | 2020 | 12 | 0.040 |
Why?
|
| Adherens Junctions | 1 | 2020 | 8 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 12 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2014 | 359 | 0.040 |
Why?
|
| Heparin | 1 | 2001 | 111 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 98 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2012 | 295 | 0.040 |
Why?
|
| Microscopy | 1 | 2020 | 88 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 274 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 344 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 662 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 127 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1300 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2019 | 19 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 82 | 0.040 |
Why?
|
| Protein Isoforms | 3 | 2007 | 196 | 0.040 |
Why?
|
| Actins | 1 | 2000 | 258 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 200 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2000 | 367 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 73 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1227 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 248 | 0.040 |
Why?
|
| Amylases | 1 | 2017 | 11 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 33 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 180 | 0.030 |
Why?
|
| Jaw | 1 | 2016 | 4 | 0.030 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 5 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 40 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2016 | 6 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 40 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 710 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 306 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 807 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 53 | 0.030 |
Why?
|
| Giant Cells | 1 | 1995 | 17 | 0.030 |
Why?
|
| Hexosaminidases | 1 | 1995 | 7 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 228 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 1995 | 82 | 0.030 |
Why?
|
| Nuclear Envelope | 1 | 1995 | 47 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 1995 | 63 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 253 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 122 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 385 | 0.030 |
Why?
|
| Plasmids | 1 | 1995 | 283 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 21 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 52 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 39 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 41 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 1995 | 169 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 74 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 243 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 16 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 70 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 98 | 0.030 |
Why?
|
| Child | 1 | 2023 | 4336 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 193 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 1993 | 16 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 113 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 1993 | 305 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1995 | 370 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 2 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 3618 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1993 | 17 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 32 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 558 | 0.030 |
Why?
|
| Clone Cells | 1 | 2013 | 106 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 28 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 32 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cell-Free System | 1 | 1992 | 31 | 0.030 |
Why?
|
| Base Sequence | 1 | 1995 | 1313 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 74 | 0.030 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 883 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 30 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 58 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 583 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1992 | 79 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 233 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 55 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1993 | 2101 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 57 | 0.020 |
Why?
|
| Axilla | 1 | 2011 | 16 | 0.020 |
Why?
|
| Groin | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 10 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 14 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 3 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 250 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1213 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1995 | 604 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 361 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 37 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 92 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 118 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 661 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 78 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2011 | 17 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 265 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1992 | 133 | 0.020 |
Why?
|
| Karyotyping | 1 | 2011 | 45 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 71 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1992 | 192 | 0.020 |
Why?
|
| Biological Transport | 1 | 1992 | 288 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 435 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 598 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 275 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 306 | 0.020 |
Why?
|
| Palliative Care | 1 | 2013 | 215 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 592 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 1918 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 943 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 296 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 272 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 454 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 256 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5262 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 329 | 0.020 |
Why?
|
| DNA Damage | 1 | 2011 | 281 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1992 | 774 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 282 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 502 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Transfection | 2 | 2001 | 676 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 855 | 0.020 |
Why?
|
| Binding Sites | 2 | 2001 | 873 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cell Line | 1 | 1992 | 2017 | 0.020 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 5 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1993 | 820 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1999 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 647 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 292 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 176 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Protein Binding | 2 | 2001 | 1566 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3218 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 509 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 927 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1470 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 33 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 35 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 65 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2001 | 41 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 175 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 190 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 209 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2001 | 77 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 219 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 376 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 443 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 258 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 558 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 425 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1040 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1993 | 60 | 0.010 |
Why?
|
| Adsorption | 1 | 1993 | 84 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 92 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 472 | 0.010 |
Why?
|
| Endocytosis | 1 | 1993 | 148 | 0.010 |
Why?
|
| Virus Replication | 1 | 1993 | 307 | 0.010 |
Why?
|